Correlation of histopathologic regression with progression free survival (PFS) in patients (pts) with RAS wildtype metastatic colorectal cancer (mCRC) under fluorouracil/folinic acid, irinotecan, and oxaliplatin (FOLFOXIRI) plus panitumumab (pmab) or FOLFOXIRI alone: Subgroup analysis of VOLFI (AIO-KRK-0109).

Stefanie Noepel-Duennebacke,Hendrik Juette,Celine Lugnier,Michael Geissler,Uwe M. Martens,Volker Heinemann,Swantje Held,Renate Klaassen-Mielke,Dominik Paul Modest,Anke Reinacher-Schick,Thomas Seufferlein,Andrea Tannapfel

Correlation of histopathologic regression with progression free survival (PFS) in patients (pts) with RAS wildtype metastatic colorectal cancer (mCRC) under fluorouracil/folinic acid, irinotecan, and oxaliplatin (FOLFOXIRI) plus panitumumab (pmab) or FOLFOXIRI alone: Subgroup analysis of VOLFI (AIO-KRK-0109).

2019

Stefanie Noepel-Duennebacke
Hendrik Juette
Celine Lugnier
Michael Geissler
Uwe M. Martens
Volker Heinemann
Swantje Held
Renate Klaassen-Mielke
Dominik Paul Modest
Anke Reinacher-Schick
Thomas Seufferlein
Andrea Tannapfel

e15024Background: We recently demonstrated improved objective response rate in untreated all-RAS wildtype mCRC with the addition of the anti-EGFR-antibody pmab to FOLFOXIRI. In this subgroup analys...

Keywords:

Progression-free survival
FOLFOXIRI
Panitumumab
Fluorouracil
Oxaliplatin
Oncology
Folinic acid
Colorectal cancer
Pathology
Irinotecan
Medicine
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations